Megan S. McAfee
Affiliations: | 2011-2015 | Molecular and Cellular Biology | Arizona State University, Tempe, AZ, United States |
Google:
"Megan McAfee"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lahman MC, Schmitt TM, Paulson KG, et al. (2022) Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency. Science Translational Medicine. 14: eabg8070 |
| Wright JH, Huang LY, Weaver S, et al. (2020) Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. Journal of Immunological Methods. 112955 |
| Ecsedi M, McAfee MS, Chapuis AG. (2020) The Anticancer Potential of T Cell Receptor-Engineered T Cells. Trends in Cancer |
| Chapuis AG, Egan DN, Bar M, et al. (2019) T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nature Medicine |
| Paulson KG, Voillet V, McAfee MS, et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications. 9: 3868 |
| Paulson KG, Perdicchio M, Kulikauskas R, et al. (2017) Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab. Journal of Clinical Oncology. 35: 3044-3044 |
| Holechek SA, McAfee MS, Nieves LM, et al. (2016) Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. Vaccine |
| Chapuis A, Egan DN, Bar M, et al. (2016) EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML Blood. 128: 1001-1001 |
| McAfee MS, Huynh TP, Johnson JL, et al. (2015) Interaction between unrelated viruses during in vivo co-infection to limit pathology and immunity. Virology. 484: 153-162 |
| Lussier DM, O'Neill L, Nieves LM, et al. (2015) Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 96-106 |